C.A.B.F. Scientific Advisory Council member Robert Findling trialing antipsychotic Abilify on 5 yr olds, America's kids on psychiatric drugs

Children in America are at high risk for being diagnosed with a mental illess and medicated for acting like kids, especially if their parents are diagnosed bipolar.

'Experts' like to call the elevated moods 'symptoms', which brings 'cyclotaxia' into the discussion and more.


Child Adolscent Bipolar Foundation is the largest parent support group on the 'Net for parents of kids with mental illness diagnoses or psychiatric 'disorders' Many are parents of children diagnosed Bipolar, ADHD, OCD and Schizophrenia. The influence begins with their Scientific Advisors, and the influence of the pharmaceutical companies is proven by the advisor's personal lives, the advisors who take money from pharma cos that make the drugs to treat these 'illnesses'. It's safe to say the site is pro-med and pro-diagnosis.

There is a parent forum where parents can share their stories with each other, and that is where I was encouraged over a decade ago to drug my child to the eyeballs for her (now wrong and removed dx) Childhood Bipolar Disorder. I was given advice by people 'inside' CABF and in particular which psych meds were the popular med cocktail of choice by 'experts'.

Back then it was Depakote, Lithobid, Zyprexa, and many kids were given benzos in the afternoon for the 5 o clock 'meltdowns' that were happening. No one questioned the 3pm dose of meds these kids were taking or withdrawal symptoms from the drugs such as antidepressants Zoloft that many were taking, and switching to and from.....


CABF bpkids Scientific Advisory council is brimming with impressive KOL's, impressive with bank accounts lined from pharmaceutical companies. Robert Findling joins the ranks with Melissa DelBello($215,000 in Q1 2011 from Eli Lilly)and Christoff Correll, Kiki Chang and of course Senator Grassley busted Joseph Biederman.


Robert Findling Seroquel XR study

Findling was the Principal Investigator of the AstraZeneca sponsored trial of the antipsychotic Seroquel XR on 10 year olds for Pediatric Bipolar Depression.

Robert Findling PubMed

Early symptoms of mania and the role of parental risk

Abstract

OBJECTIVES:

The objectives of this study were to: (i) describe the phenomenology of youths diagnosed with subsyndromal bipolar disorders; (ii) describe the phenomenology of youngsters who are the children of bipolar parents, who are also experiencing subsyndromal symptoms of bipolar disorder (patients with 'cyclotaxia'); and (iii) explore which symptoms may be most useful in identifying youths with cyclotaxia.

METHODS:
Four hundred outpatients between the ages of 5 and 17 years received a diagnostic assessment and psychometric questionnaires pertaining to mood symptomatology and psychosocial functioning. Parental diagnostic information was also obtained. Children and adolescents were assigned to one of three diagnostic groups: a 'syndromal bipolar disorder (BP)' group (n = 118), a 'sub-syndromal bipolar (SUB-BP)' group (n = 75), or a 'non-bipolar (NON-BP)' group (n = 207). In addition, based on parental diagnoses, youths were assigned to either a high genetic risk group (n = 167) or a low genetic risk group (n = 233).

RESULTS:
Youths with subsyndromal bipolar disorders were found to have intermediate degrees of manic symptoms than youths with bipolar disorder and youths without a bipolar diagnosis. Offspring of parents having a bipolar disorder were more likely to show symptoms of hypomania and mania than youths without a bipolar parent. Youths at genetic risk for developing a bipolar disorder were not found to be at higher risk for having a diagnosis of attention-deficit hyperactivity disorder or a disruptive behavior disorder. Finally, results suggest that elevated mood with irritability and rapid mood fluctuations are the key distinguishing characteristics of 'cyclotaxia'.

CONCLUSIONS:
There exists a group of youngsters who are the offspring of a parent/parents with a bipolar disorder who do not suffer from BP 1 or BP 2, yet have elevated mood symptoms and psychosocial dysfunction. As a result of these observations, treatment studies are needed for youths with 'cyclotaxia'.

Robert Findling Pharma ties (Dollars for Docs)




Findling is on the Editorial board at MedScape with Christoff Correll, both on the CABF advisor council.

MedScape Board Member details (financial disclosures)

Robert Findling

Professor of Psychiatry and Pediatrics, Case Western Reserve University, Cleveland, Ohio

Robert L. Findling, MD, has disclosed the following relevant financial relationships:

Received grants for clinical research from: Abbott Laboratories; Addrenex; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Forest Laboratories Inc; GlaxoSmithKline; Johnson & Johnson Pharmaceutical Research & Development, L.L.C; Eli Lilly and Company; Neuropharm; Otsuka Pharmaceuticals Co. Ltd; Pfizer Inc; Shire; Supernus Pharmaceuticals; Wyeth Pharmaceuticals Inc.
Served as an advisor or consultant for: Abbott Laboratories; Addrenex; AstraZeneca Pharmaceuticals LP; Biovail Corporation; Bristol-Myers Squibb Company; Forest Laboratories, Inc; GlaxoSmithKline; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; KemPharm; Eli Lilly and Company; Lundbeck Research USA, Inc; Novartis Pharmaceuticals Corporation; Organon Pharmaceuticals USA Inc; Otsuka Pharmaceutical Co., Ltd.; Pfizer Inc.; sanofi-aventis; Sepracor Inc.; Shire; Solvay Pharmaceuticals, Inc.; Supernus Pharmaceuticals; Validus; Wyeth Pharmaceuticals Inc.
Served on the speakers bureau for: Bristol-Myers Squibb Company; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Shire

Christoff Correll

Associate Professor of Psychiatry and Behavioral Sciences, Department of Psychiatry, Albert Einstein College of Medicine, Bronx, NY; Medical Director, Recognition and Prevention Program, Department of Psychiatry Research, The Zucker Hillside Hospital, Glen Oaks, New York

Christopher U. Correll, MD, has disclosed the following relevant financial relationships:

Served as an advisor or consultant for: Actelion Pharmaceuticals, Ltd; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Cephalon, Inc.; Eli Lilly and Company; Janssen Pharmaceutica Products, L.P.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; GlaxoSmithKline; F. Hoffmann-La Roche Ltd; Medicure; Otsuka Pharmaceutical Co., Ltd.; Pfizer Inc.; Schering-Plough Corporation; Supernus; Takeda Pharmaceuticals North America, Inc.; Vanda Pharmaceuticals Inc.
Served as a Data Safety Monitoring Board Member for: Bristol-Myers Squibb Company; Cephalon, Inc.; Otsuka Pharmaceutical Co., Ltd.; Supernus




Finding the kids to medicate, if they aren't meeting the criteria then something is wrong, find a reason to medicate them!


Kiki Chang, C.A.B.F Scientific Advisory council, Stanford University

Experts Close to Defining Bipolar Criteria in Children

"While rare, the occurrence of bipolar I and II disorders in children no longer seems a matter of dispute. Yet researchers and clinicians struggle to define a group of symptomatic children who don't meet full diagnostic criteria.

Based upon the number of sessions devoted to the topic at the recent annual meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), the debate over the existence— and definition—of pediatric bipolar disorder is alive and well.

However, the focus of the debate appears to have shifted a bit. After many years of deliberation, the existence of “true mania” (and therefore the potential existence of bipolar disorder itself) in children, appears to be generally agreed upon. The majority of child and adolescent psychiatrists seem to concur that while rare, distinct episodes of mania that would meet DSM-IV diagnostic criteria for bipolar I disorder, can and do occur in children, said Kiki Chang, M.D., an assistant professor of psychiatry at Stanford University.

“Bipolar II,” Chang continued, “is harder [to diagnose in children], but still definable.” Chang chaired one of many sessions on pediatric bipolar disorder during the AACAP annual meeting in Toronto in October. “BP-NOS [not otherwise specified], is harder even still,” he said."

"Still Definable" says Kiki Chang

Kiki Chang pharma ties

Kiki Chang



Currently Recruiting!

Study of Aripiprazole (Abilify) Versus Placebo in Children With Subsyndromal Bipolar Disorder



Purpose

"The purpose of this study is to test the effectiveness and tolerability/safety of aripiprazole (abilify) in children with subsyndromal symptoms of bipolar disorder who also have a bipolar parent and other family member with a mood disorder."



The heavy cloak of pharmaceutical influence and tainted KOL's (Key Opinion Leaders)defining, defining which kids are vulnerable to 'mental illness' is part of the epidemic that has entrenched America. The mental illness epidemic that the pharmaceutical companies push, via lining these doctors of influence pockets with cold cash, and the prestige created within the psychiatric circle is a frightening portrayal of the new culture in America. The new way of defining illness and children.

Once the kids are medicated, there are no longer baselines of kids for anyone to see. Children are lively, high spirited, wiggle, and talk too much. If they don't teachers and parents question if they are now depressed. If they are too lively, they could be subsymdronal bipolar, on the cusp of being defined bipolar, which appears according to these studies and KOL opinions, is not too far off.



The ramifications of drugging young for mental illness and preventative measures, are enormous.


A life lived on psych meds and on the growing brain has negative outcomes, I know, because my daughter is re-learning how to speak in sentences and take showers daily at age 23 as a result of this medication based medical model America calls psychiatry.